Grants and Contributions:
Title:
Discovery and Preclinical Development of Novel Compounds for Niemann-Pick Type C Disease
Agreement Number:
910465
Agreement Value:
$200,000.00
Agreement Date:
Jul 1, 2018 - Jun 30, 2019
Description:
Novel targeted small molecule modulators will be designed, tested and characterized as disease-modifying therapeutics for Niemann-Pick Type C disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5A 4B5
Reference Number:
172-2018-2019-Q2-910465
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
851456152
Recipient Type:
For-profit organization
Recipient's Legal Name:
Alectos Therapeutics Inc.
Federal Riding Name:
Burnaby North--Seymour
Federal Riding Number:
59002
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710